Evidence map›Paper›PMID 42741434›Full record

ArticleFrontiers in hematology2024

Novel cryopreservation medium for enhanced stability of T cells at -80°C.

WenXuan Zhou, Chen Wang, Yao Shi, Yi Pan, XiaDuo Meng, XunLei Kang, Xu Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

WenXuan ZhouCenter for Precision Medicine, Department of Medicine, University of Missouri School of Medicine, Columbia, MO, United States.
Chen WangCenter for Precision Medicine, Department of Medicine, University of Missouri School of Medicine, Columbia, MO, United States.
Yao ShiCenter for Precision Medicine, Department of Medicine, University of Missouri School of Medicine, Columbia, MO, United States.
Yi PanCenter for Precision Medicine, Department of Medicine, University of Missouri School of Medicine, Columbia, MO, United States.
XiaDuo MengCenter for Precision Medicine, Department of Medicine, University of Missouri School of Medicine, Columbia, MO, United States.
XunLei KangCenter for Precision Medicine, Department of Medicine, University of Missouri School of Medicine, Columbia, MO, United States.
Xu HanWake Forest Institute of Regenerative Medicine, School of Medicine, Wake Forest University, Winston-Salem, NC, United States.

Funding

Membrane protein target for leukemia therapyR37CA241603 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI KANG, XUNLEI · 2020 to 2025
$2.9M
Innovation of Biobanking for Cellular Adoptive Immunotherapies Based on a First-in-Class Biocompatible Cryopreservation Technology for T and NK Cells and Their CAR-Engineered ProductsR44CA278579 · NCI · CRYOCRATE, LLC · PI HAN, XU · 2022 to 2023
$1.8M
NCI NIH HHS R37 CA241603NCI NIH HHS R44 CA278579
6 · The paper itself

Abstract

The increasing demand for immune cell applications, both in clinical settings and in research laboratories, has highlighted the critical need for cryopreservation (banking) methods for T cells. While conventional techniques such as freezing with liquid nitrogen remain prevalent, they pose significant challenges including high equipment costs, safety considerations, and logistical hurdles in transportation. Our cryopreservation medium, C80EZ

Indexed as

C80EZcryopreservationDMSOimmunotherapyT cell

Identifiers

PMID42741434
PMCPMC13573834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.